Call
+918447748545

Published on: Jul 22, 2020
2 minute read
By: Dr Rajan Choudhary

The Oxford Vaccine

Recently we wrote a blog on the success of an RNA vaccine against SARS-CoV-2, the virus responsible for COVID-19. Within just a few weeks of that incredible research breakthrough, researchers at Oxford University’s Jenner Institute have announced a COVID vaccine that has induced remarkable immune response against the virus.

This study was published in the Lancet, one of the most prestigious medical journals in the world, and a simple summary suggests the vaccine has no early safety concern and is able to induce a strong immune response with both T cells and B cell/antibodies.

THE VACCINE

ChAdOx1 nCoV-19, now known as AZD1222, was co-developed by the University of Oxford and one of its spin-off companies, Vaccitech. The vaccine uses a viral vector based on a common cold virus (adenovirus). This carries genetic material for the SARS-CoV-2 spike protein. In our previous blog, we saw how the spike proteins are used by the virus to target and fuse with our target cells, allowing the virus to invade, replicate and ultimately cause the disease known as COVID. It is also a good target for the human immune system to recognize and attack.

The viral vector delivers the genetic material inside our cells. The spike protein is then produced by our cells, recognized by the immune system as a viral target, and an immune response is created against it. This can be antibodies, which recognize, attach to and mark the virus in our blood, allowing for other white blood cells to destroy the virus.

In this case, the vaccine also produced a T cell response. T cells can recognize cells infected by a virus-based on the markers present on the surface of infected cells. They can tell an infected cell to destroy itself, thereby destroying the virus within without spreading the infection. They also have other functions that we will not discuss in this blog.

THE STUDY

This study was a Phase I/II trial that started in April using the vaccine named ChAdOx1 nCoV-19. This vaccine development started in January 2020, and progress on development has been incredibly rapid. Whilst our previous study had just 45 people, this study looked reviewed over 1,000 healthy adults. 10 of these participants received two doses of the vaccine.

In a study the more participants there are, the greater the power of the study. If the vaccine has any side effects, even ones that rarely occur, it is more likely to be picked up in studies with more people. Similarly having more people helps show that the vaccine is effective, and the strong responses are not merely a fluke or accident. Another benefit of this study is it was able to compare the vaccine against a control group. This shows the results were not simply a placebo and allowed comparison of side effects as well.

The majority of side effects were feeling feverish, chills, muscle ache, headache, and malaise, all symptoms treatable with paracetamol. None of the participants had any serious side effects. It took just 14 days to create a T cell response, and 28 days to make strong antibodies. In 91% of patients, this was enough to neutralize the COVID coronavirus. Receiving two doses gave an even stronger antibody response, and all participants were able to stop the virus.

WHAT NEXT

The news from the University of Oxford is needed, as infection rate and mortality continue to increase in countries such as the US and Brazil. The ability to induce an antibody response without causing harm to the patient shows we have made huge progress in the fight against COVID-19. Further Large scale Phase III trials been set up through a global partnership, and include studies in the US with over 30,000 patients, studies in children as well as some in low to middle-income countries.

If successful a vaccine would be essential in preventing a second wave of COVID in the winter when the elderly population is most at risk. And it would be the key to restarting the economy and getting our everyday lives back to where it was pre-pandemic.

Read Blog

Digital Pharmacy Platforms India: How SecondMedic Is Transforming Medicine Access Through Technology

India’s healthcare system is rapidly digitizing, and one of the most impactful innovations is the rise of digital pharmacy platforms. These platforms make it easier for people to order medicines online, manage prescriptions, and access healthcare services without visiting a physical store.

As chronic diseases, online consultations, and digital health records become more common, digital pharmacy solutions are now a vital part of India's healthcare infrastructure. SecondMedic plays a key role in this evolution by providing secure, fast, and integrated digital pharmacy services.

What Are Digital Pharmacy Platforms?

Digital pharmacy platforms are online systems that allow users to:

Order prescription medicines
Upload or sync digital prescriptions
Schedule refills
Purchase OTC products
Track orders
Access pharmacist support

Instead of visiting a traditional pharmacy, users can manage medication needs from anywhere in India.

Why Digital Pharmacies Matter in India

India sees high demand for medicines due to:

Rising chronic diseases
Aging population
Urban mobility challenges
Increasing telemedicine adoption
Growing digital health awareness

Digital pharmacies bridge the gap between medical consultation and medication access.

Key Benefits of Digital Pharmacy Platforms

1. Convenience and Accessibility

Patients can order medicines anytime, especially helpful for elderly individuals or those living in remote areas.

2. Time and Cost Savings

Digital ordering eliminates long queues, multiple store visits, and pricing uncertainties.

3. Verified, Authentic Medicines

Reputed platforms ensure drugs come from licensed pharmacies with full batch traceability.

4. E-Prescription Integration

Digital prescriptions reduce manual errors and support seamless ordering.

5. Chronic Disease Medication Management

Automated refill reminders and scheduled deliveries help maintain treatment consistency.

6. Privacy and Discretion

Useful for sensitive medication categories where users may prefer confidential ordering.

The Growing Digital Pharmacy Market in India

According to Statista 2025:

The Indian e-pharmacy market is expected to reach USD 10 billion by 2027.
Nearly 35 percent of urban households now use digital pharmacy services.
Chronic disease patients are the largest user segment.

Government initiatives like ABDM also promote secure and standardized digital prescriptions.

SecondMedic’s Digital Pharmacy Ecosystem

SecondMedic integrates pharmacy services seamlessly within its broader digital health platform.

1. Online Medicine Ordering

Users can order medicines directly through the SecondMedic app or website.

2. E-Prescription Sync

Prescriptions from SecondMedic doctors sync automatically, reducing errors and delays.

3. Verified Inventory

All medicines are sourced from certified pharmacies with temperature-controlled storage and valid expiry cycles.

4. Chronic Care Refill System

For diabetes, hypertension, thyroid disorders, and cardiac conditions, patients can schedule monthly refills.

5. Real-Time Tracking

Users get live updates on order status, dispatch, and delivery.

6. Secure Payment Gateway

Digital payments are supported through encrypted channels, ensuring safety and transparency.

7. Integration with Medical Consultations

After virtual consultations, prescribed medicines can be ordered instantly on the same platform.

How Digital Pharmacy Platforms Support Telemedicine

Telemedicine has become a cornerstone of modern healthcare. Digital pharmacies complement this by:

Enabling immediate access to prescribed medicines
Ensuring continuity of care
Reducing patient dependency on physical pharmacies
Streamlining doctor-to-pharmacy communication

Together, they create an efficient, patient-centered care loop.

Challenges in India’s Pharmacy System and How Digital Platforms Solve Them

1. Fragmented Pharmaceutical Distribution

Digital systems bring transparency and accountability.

2. Prescription Mismanagement

E-prescriptions minimize errors and duplication.

3. Limited Accessibility in Rural Areas

Digital ordering delivers medicines directly to underserved regions.

4. Inconsistent Medicine Availability

Real-time inventory ensures availability and alternatives.

5. Lack of Patient Awareness

Digital platforms offer information on dosage, interactions, and side effects.

Regulatory Framework for Digital Pharmacies in India

To ensure safety and compliance, digital pharmacies follow:

Drugs and Cosmetics Act (1940)
Pharmacy Practice Regulations
ABDM standards for digital prescriptions
DPDP Act for data security
CDSCO guidelines for online pharmacies

SecondMedic maintains full compliance with regulatory requirements.

Future of Digital Pharmacy in India

The sector is expected to grow due to:

AI-based medicine recommendations
Smart refill systems
Blockchain for supply chain verification
Automated pharmacy logistics
Drone-based delivery pilots in some states

SecondMedic is actively building tools to support next-generation pharmacy automation and integrated digital care.

Why Patients Trust SecondMedic’s Pharmacy System

Authentic and verified medicines
Transparent pricing and secure payments
Direct connection with healthcare consultations
Support for chronic care medication
Nationwide delivery capability
User-friendly ordering process
Compliance with all digital health safety standards

SecondMedic brings reliability, convenience, and safety under one unified digital healthcare platform.

Conclusion

Digital pharmacy platforms are redefining how India accesses medicines. They improve convenience, enhance safety, support telemedicine, and empower patients to manage chronic conditions more effectively. SecondMedic’s digital pharmacy provides an integrated solution that combines e-prescriptions, secure ordering, and nationwide delivery to simplify healthcare access.

To order medicines or explore digital pharmacy services, visit www.secondmedic.com

References

Statista – India E-Pharmacy Market Outlook 2025
IMARC Group – Digital Healthcare Market India 2025
NITI Aayog – Digital Health Tech Landscape 2024
ABDM – Digital Prescription Guidelines
FICCI – Healthcare Innovation Report 2024

Request A Callback

+91

By using this website/app, I confirm that I am at least 18 years old and consent to the processing of my personal data in accordance with the Terms of Service, Privacy Policy, and Declaration.